$AORT

Holloway Jean F sold $28K of AORT

Holloway Jean F (SVP, General Counsel) sold 977 shares of ARTIVION, INC. (AORT) at $28.49 on 2026-08-12.

Original reporting
SEC EDGAR · Holloway Jean F
Published Aug 12, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AORT
Neutral
medium confidence
Mentioned
$AORT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AORTNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include new operational, financial, or regulatory information about Artivion.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but there is no direct fundamental catalyst in the filing.

03

What to watch

The article provides only the sale size and price, not the insider’s broader trading history, tax situation, or whether other insiders or institutions acted around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-12, after-hours disclosure window

Background

This is an SEC Form 4 insider transaction disclosure for Artivion, Inc. (AORT).

Company-level read

Ticker impact

$AORTNeutralMedium confidence
Context

Artivion disclosed an insider open-market sale by SVP and General Counsel Holloway Jean F of 977 shares at $28.49 on 2026-08-12.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction (open-market sale) with no 10b5-1 plan and no accompanying company-specific news, so the incremental information is modest.

Market effects

No clear sector read-through from a single insider sale without additional company or regulatory developments.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or tax needs; absence of a 10b5-1 plan does not necessarily imply negative expectations.

Key entities

  • ARTIVION, INC.

    Company whose insider transaction was reported on Form 4.

  • Holloway Jean F

    SVP and General Counsel who sold 977 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AORTMed

Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem

Artivion Inc. (AORT) reported Q2 2026 revenue growth of 11% to $125.8M, driven by its aortic arch portfolio. However, it posted a net loss of $13.5M, reversing from a profit a year earlier. The company completed the Endospan acquisition and received FDA approval for AMDS. Despite growth, profitability declined, and guidance was reiterated without an increase.

$AORTMed

Why Artivion (AORT) Stock Is Trading Up Today

Artivion (AORT) shares rose 2.5% after Canaccord Genuity raised its price target to $40, citing strong Q2 revenue of $125.8M. The stock later cooled to $29.57, up 2.3%. The company's shares have been volatile, with a 26.8% drop in May after missing earnings estimates and lowering guidance. AORT is down 33.5% YTD.

$AORTMedAI 8/10

Artivion (AORT) Q2 2026 Earnings Call Transcript

Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.

$AORTMed

Artivion: Q2 Earnings Snapshot

Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.